Scarica l'app Stockscreener
11.88
0.85%
0.10
Dopo l'orario di chiusura:
11.88
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics, Inc. Revenue Breakdown – NASDAQ:DSGN - TradingView
DSGN|Design Therapeutics Inc|Price:11.780|Chg%:+0.150 - TradingKey
Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate - Moomoo
Fuchs Dystrophy Pipeline 2026: Therapies Under Investigation, - openPR.com
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history - Yahoo Finance UK
Cellares and Papillon partner for PPL-001 manufacturing automation - Yahoo Finance
Design Therapeutics (DSGN) Q1 2026 earnings summary - Quartr
Design Therapeutics (DSGN) Leerink Global Healthcare Conference 2026 Summary - Quartr
Design Therapeutics (DSGN) Jefferies London Healthcare Conference 2024 Summary - Quartr
Design Therapeutics (DSGN) Proxy filing Summary - Quartr
Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
Design Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Shares as Investors Focus on Pipeline ProgressFinancial Health Score - dars.gov.et
DSGN Q1 2026 Earnings: EPS Surprises to the Upside Amid Ongoing Pipeline DevelopmentEPS Surprise History - dars.gov.et
Myotonic Dystrophy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Bioscien - Barchart.com
Myotonic Dystrophy Market Expected to Experience Accelerated - openPR.com
Design Therapeutics (DSGN) Jefferies Global Healthcare Conference 2025 Summary - Quartr
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
If You Invested $1,000 in Design Therapeutics, Inc. (DSGN) - Stock Titan
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN - TradingView
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
Cantor Fitzgerald reiterates Design Therapeutics stock rating - Investing.com
Cantor Fitzgerald reiterates Design Therapeutics stock rating By Investing.com - Investing.com Nigeria
Design Therapeutics stock rises on Phase 1 trial dosing start - Investing.com
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com - Investing.com Nigeria
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com - Investing.com South Africa
Design Therapeutics begins dosing DM1 drug in phase 1 trial - Investing.com
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - The Manila Times
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause - Stock Titan
Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma - Barchart.com
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Smaller-than-Expected Loss Lifts Shares 5.28%Segment Revenue Breakdown - dars.gov.et
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 2000 Growth Benchmark - marketscreener.com
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark - marketscreener.com
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug - Benzinga
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Sahm
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN) - TradingView
Design Therapeutics, Inc. Actuals & Estimates (BOATS:DSGN) - TradingView
DSGN Forecast — Price Target — Prediction for 2027 - TradingView
DSGN News | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Design Therapeutics, Inc. (DSGN) is up 6.92% in one week: What you should know - MSN
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts - Seeking Alpha
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DSGN Q1 2026 Earnings: Narrowed Loss Beats Expectations as Pipeline AdvancesRevenue Warning Signal - dars.gov.et
ODTX Stock Price and Chart — NASDAQ:ODTX - TradingView
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - Business Wire
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):